This event is no longer in the live catalog. Showing its last saved snapshot.

FDA decision: Venglustat by Sanofi (in 2026)
K 2.1K contracts
1
1
AI Analysis
Trader mode: Market mechanics, assumptions and risks
K 2.1K contracts
Reported volume · provider units
1
Saved contracts
0
Same-question pairs
Source snapshot: Nov 19, 2026, 12:00 AM UTC
Snapshot observed Nov 12, 2026, 3:00 AM UTC. This analysis describes that snapshot and is not a live news update.
What the contract measures
This contract asks what the FDA's decision on venglustat, an oral drug from Sanofi, will be in 2026. The stated rule is that the market "resolves to Yes" if the decision "is a full approval or an accelerated approval" [1]. It resolves to No for a denial, a sponsor withdrawal, a conditional approval, or if no decision is issued [1]. The drug is described as a substrate reduction therapy for Gaucher disease [1]. The contract is a yes or no question about one regulatory outcome, so the two outcomes do not overlap.
Reading the snapshot
The saved snapshot was observed at Nov 12, 2026, 3:00 AM UTC and retrieved at Nov 12, 2026, 4:08 AM UTC [1]. It shows a Yes price of 0.825 and a No price of 0.175 [1]. These are prices recorded at that moment. They are not executable quotes and not verified probabilities. The two prices sum to 1.00 in this record, but that alone does not show how a trader could act on them.
The coverage record lists one market from one provider event, with no partial sampling [1]. The sample therefore contains only this contract, and it cannot be compared with other platforms or events.
The market record gives an end date of Jan 8, 2027, 3:00 PM UTC [1]. The excerpt separately says the listed end time is not supplied and that the market will close early if the FDA issues a decision before January 1, 2027 [1]. A close time is when trading is scheduled to end, not when the outcome is known. The source does not state when or whether an FDA decision will be issued.
What remains uncertain
The evidence does not explain why the prices are where they are, and it does not show how many traders hold each position. The volume and trader activity are not included in the supplied material. The source also does not report any recent news about venglustat, any FDA schedule, or how often prices like these have matched later outcomes.
Because the snapshot is a single moment, it may not reflect current prices. The contract has not resolved according to the supplied evidence. Readers should treat the figures as a record of what the provider showed at one time, and should check the live source before drawing conclusions.
References
- Kalshi: FDA decision: Venglustat by Sanofi (in 2026). Provider data observed Nov 12, 2026, 3:00 AM UTC.
Snapshot observed Nov 12, 2026, 3:00 AM UTC. This analysis describes that snapshot and is not a live news update.
What the contract measures
This is a single Kalshi market tied to the event "FDA decision: Venglustat by Sanofi (in 2026)" [1]. The question asks, "What will the FDA's decision be on Venglustat by Sanofi in 2026?" [1]. The contract resolves to Yes "if the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval" [1]. It resolves to No if the decision is "a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued" [1].
The rules also say the market "will close early if the FDA issues a decision on Venglustat before Jan 1, 2027" [1]. This is a contract condition, not a statement that a decision is expected on any particular date. The listed market end date is Jan 8, 2027, 3:00 PM UTC [1]. The event record separately states "Listed end time: not supplied" [1]. Readers should treat the listed date as the provider's stored close time and check the platform's own rules before relying on it.
Reading the snapshot
The provider observation time is Nov 12, 2026, 3:00 AM UTC, and the source was retrieved at Nov 12, 2026, 4:08 AM UTC [1]. These prices describe that observation only, not live trading now. The saved Yes price is 0.825 and the No price is 0.175 [1]. These are snapshot prices, not executable quotes, and they are not verified probabilities of approval.
The sample covers one market from one provider event. The coverage record shows one market included, with no partial sample flagged [1]. Even so, the sample warning states that the included markets "does not establish that the providers list every possible real-world outcome" [1]. The sample cannot tell you whether other outcomes exist beyond the rules listed above.
No other platform's contract is included, so no cross-platform comparison is possible. Different wording or close times on other platforms would require separate reading of their own rules.
What remains uncertain
The evidence does not explain why the price is where it is, how many traders hold each side, or how much volume or liquidity supports the quote. It also does not describe recent news about Venglustat or the FDA review. The excerpt gives no information about when a decision may occur, so the timing of resolution remains unknown from this source.
References
- Kalshi: FDA decision: Venglustat by Sanofi (in 2026). Provider data observed Nov 12, 2026, 3:00 AM UTC.
AI-generated analysis based on market data. Not financial advice.
Saved Nov 12, 2026 UTCOverview
This PredictPedia entry covers a Kalshi contract, titled "FDA decision: Venglustat by Sanofi (in 2026)," that asks how the U.S. Food and Drug Administration's decision on venglustat will be classified in 2026. The contract is a single market in the saved event. Its rules say the market resolves to Yes if the FDA's decision is a full approval or an accelerated approval [1]. The contract rules also set out the No outcomes. The market resolves to No if the FDA issues a denial (described in the rules as a CRL being issued), if the sponsor withdraws the application, if the FDA grants a conditional approval, or if no decision is issued [1]. Because conditional approval and the absence of a decision both lead to No, the contract is narrower than a general question about whether the drug will reach the market. Venglustat is described in the contract as an oral small-molecule drug developed by Sanofi. The rules state that it slows the body's production of glucosylceramide, a fatty substance that builds up to harmful levels in people with Gaucher disease. It belongs to a class called substrate reduction therapy, which targets the upstream source of the problem rather than replacing a missing enzyme [1]. The rules note that because the drug is taken by mouth and designed to cross into the brain, it may address neurological symptoms that older enzyme-based treatments cannot reach [1]. These are descriptions taken from the contract text, not independent assessments of the drug. The contract lists an end date of January 8, 2027 at 15:00 UTC. That date comes from the market data and is not an announced date for an FDA decision. The rules also state that the market will close early if the FDA issues a decision on venglustat before January 1, 2027 [1].
Why It Matters
The contract measures whether a regulatory outcome for one drug, venglustat, falls into a specific category of FDA decision during 2026. Under its rules, a full or accelerated approval resolves Yes, while a denial, sponsor withdrawal, conditional approval, or no decision resolves No [1]. Prices on the contract are therefore tied to how the market expects the FDA process to end, within the category definitions written in the rules. The price is a snapshot from the provider's observation time and is not a verified probability or an executable quote.
Snapshot context
The latest published provider snapshot for this topic was observed on 2026-11-12 at 03:00 UTC. It contains listings from Kalshi. Market descriptions and listed closing times define the contracts; they do not establish that the real-world outcome has occurred. This article does not include a separately verified news update. [1]
Frequently Asked Questions
What outcome makes this contract resolve to Yes?
The market resolves to Yes if the FDA's decision on venglustat in 2026 is a full approval or an accelerated approval [1].
Which outcomes resolve the contract to No?
The contract resolves to No if the FDA issues a denial, which the rules describe as a CRL being issued, if the sponsor withdraws, if the FDA grants a conditional approval, or if no decision is issued [1].
When could the contract close early?
The rules say the market will close early if the FDA issues a decision on venglustat before January 1, 2027 [1].
What did the price show at the time of the snapshot?
At the provider's observation time, the Yes outcome was priced at 0.825 and the No outcome at 0.175 [1]. These are snapshot prices, not executable quotes or verified probabilities.
AI-written background. References identify the evidence used; Wikipedia links under Learn More are additional reading. Prices and provider rules are dated snapshots. This is not financial advice.
Related prediction markets
Prices are catalog snapshots and may have changed. Check each market's rules and observation time.

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
K 4.2K contracts
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
K 1.8K contracts
FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)
K 944.1 contracts
FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)
K 75.66 contracts
When will Trump nominate an FDA commissioner?
K 1.6K contracts
FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)
K 434.76 contractsMarket Insights
Price gaps of 2 pp+
0
Same-question pairs
0
No outcomes on this page have been reviewed as the same question on both platforms yet.
Price differences do not establish arbitrage. Check each pair's review, current order prices, fees and settlement rules.
